Tonix Pharmaceuticals has initiated a Phase 2 trial, called OASIS, to evaluate TNX-102 SL for reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD) in motor vehicle collision survivors. The University of North Carolina is sponsoring the trial with a $3 million grant from the Department of Defense. Results are anticipated in the latter half of 2026.
This trial addresses a critical unmet need for early intervention after trauma. Currently, no approved medications exist to manage the immediate psychological impact of traumatic events like car accidents or combat experiences. Successful results could significantly alter the clinical trajectory for trauma survivors, potentially preventing the development of chronic conditions like PTSD. This has important implications for both civilian and military populations, given the prevalence of trauma exposure. The trial’s focus on early intervention could prevent or mitigate the long-term consequences of trauma, improving overall recovery and reducing the burden of chronic stress disorders.
OASIS will enroll around 180 participants across multiple U.S. emergency departments, comparing TNX-102 SL to a placebo over a two-week treatment period. This research leverages the existing infrastructure and knowledge base of the UNC-led AURORA initiative, a substantial national effort aimed at understanding and improving trauma recovery. TNX-102 SL, a sublingual cyclobenzaprine formulation, has shown promise in improving sleep quality in individuals with PTSD, with prior studies suggesting positive effects on sleep and stress-related symptoms in the initial weeks of treatment.
Positive results from the OASIS trial could position TNX-102 SL as a first-in-class treatment for ASR and ASD, establishing a new standard of care in trauma recovery. This would represent a significant advancement in the field and could transform how acute stress reactions are managed, ultimately improving long-term outcomes for trauma survivors. Moreover, success in this trial could expand the clinical applications of TNX-102 SL, further solidifying its therapeutic value and potentially opening new markets for Tonix Pharmaceuticals.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
